RNA-Based Therapies

Drug Discovery Handbook

Volumn , Issue , 2005, Pages 1259-1308

  Pascolo, Steve ^a  

^a CureVac GmbH   (Germany)

Author keywords

RNA for immunostimulation; RNA based therapies; Synthetic RNA for gene regulation

Indexed keywords

EID: 83155172466     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0471728780.ch27     Document Type: Chapter

References (137)

1. Palade,G. E. (1955). A small particulate component of the cytoplasm. J. Biophys. Biochem. Cytol., 1, 59-68.
2. Littlefield, J.W., Keller, E. B., Gross, J., Zamecnik, P. C. (1955). Studies on cytoplasmic ribonucleoprotein particles from the liver of the rat. J. Biol. Chem., 217, 111-123.
3. Crick, F. (1970). Central dogma of molecular biology. Nature, 227, 561-563.
4. Brenner, S. J. F. M. M. (1961). An unstable intermediate carrying information from genes to ribosome for protein synthesis. Nature, 190, 576-581.
5. Gros, F., Gilbert,W., Hiatt, H. H., Attardi, G., Spahr, P. F., Watson, J. D. (1961). Molecular and biological characterization of messenger RNA. Cold Spring Harb. Symp. Quant. Biol., 26, 111-132.
6. Hoagland, M. B., Stephenson, M. L., Scott, J. F., Hecht, L. I., Zamecnik, P. C. (1958). A soluble ribonucleic acid intermediate in protein synthesis. J. Biol. Chem., 231, 241-257.
7. Feldmann, H., Zachau, H. G. (1964). Chemical evidence for the 3¢-linkage of amino acids to s-RNA+. Biochem. Biophys. Res. Commun., 15, 13-17.
8. Chapeville, F., Lipmann, F., Von Ehrenstein, G., Weisblum, B., Ray, W. J., Jr., Benzer, S. (1962). On the role of soluble ribonucleic acid in coding for amino acids. Proc. Natl. Acad. Sci. USA, 48, 1086-1092.
9. Absher, M., Stinebring, W. R. (1969). Toxic properties of a synthetic doublestranded RNA. Endotoxin-like properties of poly I. poly C, an interferon stimulator. Nature, 223, 715-717.
10. Guerrier-Takada, C., Gardiner, K., Marsh, T., Pace, N., Altman, S. (1983). The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell, 35, 849-857.
11. Cech,T. R., Bass,B. L. (1986). Biological catalysis by RNA. Annu. Rev.Biochem., 55, 599-629.
12. Delihas, N. (1995). Regulation of gene expression by trans-encoded antisense RNAs. Mol. Microbiol., 15, 411-414.
13. Tuschl, T., Borkhardt, A. (2002). Small interfering RNAs: A revolutionary tool for the analysis of gene function and gene therapy. Mol. Interv., 2, 158-167.
14. Matzke, M., Matzke, A. J. (2003). RNAi extends its reach. Science, 301, 1060-1061.
15. Schramke, V., Allshire, R. (2003). Hairpin RNAs and retrotransposon LTRs effect RNAi and chromatin-based gene silencing. Science, 301, 1069-1074.
16. Yao, M. C., Fuller, P., Xi, X. (2003). Programmed DNA deletion as an RNAguided system of genome defense. Science, 300, 1581-1584.
17. Deutscher, M. P., (1993). Ribonuclease multiplicity, diversity, and complexity. J. Biol. Chem., 268, 13011-13014.
18. Egli, M., Gryaznov, S. M. (2000). Synthetic oligonucleotides as RNA mimetics: 2¢-Modified Rnas and N3¢ Æ > P5¢ phosphoramidates. Cell Mol. Life Sci., 57, 1440-1456.
19. Koshkin,A. A.,Wengel, J. (1998). Synthesis of novel 2¢,3¢-linked bicyclic thymine ribonucleosides. J. Org. Chem., 63, 2778-2781.
20. Wittenhagen, L. M., Kelley, S. O. (2003). Impact of disease-related mitochondrial mutations on tRNA structure and function. Trends Biochem. Sci., 28, 605-611.
21. Andrake, M., Guild,N., Hsu,T., Gold, L., Tuerk,C., Karam, J. (1988). DNA polymerase of bacteriophage T4 is an autogenous translational repressor. Proc. Natl. Acad. Sci. USA, 85, 7942-7946.
22. Powers,T., Daubresse, G., Noller, H. F. (1993). Dynamics of in vitro assembly of 16 S rRNA into 30 S ribosomal subunits. J. Mol. Biol., 232, 362-374.
23. Sullenger, B. A., Gallardo, H. F., Ungers, G. E., Gilboa, E. (1990). Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell, 63, 601-608.
24. Tuerk,C., Gold, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249, 505-510.
25. Ellington, A. D., Szostak, J.W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature, 346, 818-822.
26. Daniels, D. A., Chen, H., Hicke, B. J., Swiderek, K. M., Gold, L. (2003). A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment. Proc. Natl.Acad. Sci.USA, 100, 15416-15421.
27. Lee, J. F., Hesselberth, J. R., Meyers, L. A., Ellington, A. D. (2004). Aptamer database. Nucleic Acids Res., 32 Database issue, D95-100.
28. Aurup, H., Williams, D. M., Eckstein, F. (1992). 2¢-Fluoro-and 2¢-amino-2¢-deoxynucleoside 5¢-triphosphates as substrates for T7 RNA polymerase. Biochemistry, 31, 9636-9641.
29. Melbye, S. W., Brant, B. A., Freedberg, I. W. (1977). Epidermal nucleases. III. The ribonucleases of human epidermis. Br. J. Dermatol., 97, 355-364.
30. Lorger, M., Engstler, M., Homann, M., Goringer,H.U. (2003).Targeting the variable surface of African trypanosomes with variant surface glycoprotein-specific, serum-stable RNA aptamers. Eukaryot. Cell, 2, 84-94.
31. Darfeuille, F., Arzumanov, A., Gryaznov, S., Gait, M. J., Di Primo, C., Toulme, J. J. (2002). Loop-loop interaction of HIV-1 TAR RNA with N3¢ Æ P5¢ deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated transcription. Proc. Natl. Acad. Sci. USA, 99, 9709-9714.
32. Darfeuille, F., Arzumanov, A., Gait, M. J., Di Primo, C., Toulme, J. J. (2002). 2¢-O-methyl-RNA hairpins generate loop-loop complexes and selectively inhibit HIV-1 Tat-mediated transcription. Biochemistry, 41, 12186-12192.
33. Darfeuille, F., Hansen, J. B., Orum, H., Di Primo, C., Toulme, J. J. (2004). LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1. Nucleic Acids Res., 32, 3101-3107.
34. Hicke, B. J., Stephens, A. W. (2000). Escort aptamers: A delivery service for diagnosis and therapy. J. Clin. Invest., 106, 923-928.
35. White, R. R., Sullenger, B. A., Rusconi, C. P. (2000). Developing aptamers into therapeutics. J. Clin. Invest., 106, 929-934.
36. Sayer, N., Ibrahim, J., Turner, K., Tahiri-Alaoui, A., James,W. (2002). Structural characterization of a 2¢ F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120. Biochem. Biophys. Res. Commun., 293, 924-931.
37. Bock, L. C., Griffin, L. C., Latham, J. A., Vermaas, E. H., Toole, J. J. (1992). Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature, 355, 564-566.
38. Santulli-Marotto, S., Nair, S. K., Rusconi, C., Sullenger, B., Gilboa, E. (2003). Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res., 63, 7483-7489.
39. Homann, M., Goringer, H. U. (1999). Combinatorial selection of high affinity RNA ligands to live African trypanosomes. Nucleic Acids Res., 27, 2006-2014.
40. Sayer, N. M., Cubin, M., Rhie, A., Bullock, M., Tahiri-Alaoui, A., James, W. (2004). Structural determinants of conformationally selective, prion-binding aptamers. J. Biol. Chem., 279, 13102-13109.
41. Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette,W. L., Henninger, D. D., Claesson-Welsh, L., Janjic, N. (1998). 2¢-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem., 273, 20556-20567.
42. Drolet,D.W., Nelson, J., Tucker, C. E., Zack, P. M., Nixon, K., Bolin, R., Judkins, M. B., Farmer, J. A., Wolf, J. L., Gill, S. C., Bendele, R. A. (2000). Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res., 17, 1503-1510.
43. (2003). Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology, 110, 979-986.
44. Csaky, K. (2003). Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: Promises and pitfalls. Ophthalmology, 110, 879-881.
45. Pestka, S., Daugherty, B. L., Jung, V., Hotta, K., Pestka, R. K. (1984). AntimRNA: specific inhibition of translation of single mRNA molecules. Proc. Natl. Acad. Sci. USA, 81, 7525-7528.
46. Coleman, J., Green, P. J., Inouye, M. (1992). The use of RNAs complementary to specific mRNAs to regulate the expression of individual bacterial genes. Biotechnology, 24, 253-260.
47. Izant, J. G., Weintraub, H. (1985). Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA. Science, 229, 345-352.
48. Kurreck, J. (2003). Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem., 270, 1628-1644.
49. Kruger, K., Grabowski, P. J., Zaug, A. J., Sands, J., Gottschling,D. E., Cech,T. R. (1982). Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell, 31, 147-157.
50. Doudna, J. A., Cech,T. R. (2002). The chemical repertoire of natural ribozymes. Nature, 418, 222-228.
51. Unrau, P. J., Bartel, D. P. (1998). RNA-catalysed nucleotide synthesis. Nature, 395, 260-263.
52. Lohse, P. A., Szostak, J.W. (1996). Ribozyme-catalysed amino-acid transfer reactions. Nature, 381, 442-444.
53. Haseloff, J., Gerlach,W. L. (1988). Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature, 334, 585-591.
54. Eckstein, F. (1996). The hammerhead ribozyme. Biochem. Soc. Trans., 24, 601-604.
55. Anderson, P., Monforte, J., Tritz, R., Nesbitt, S., Hearst, J., Hampel, A. (1994). Mutagenesis of the hairpin ribozyme. Nucleic Acids Res., 22, 1096-1100.
56. Earnshaw, D. J., Gait, M. J. (1997). Progress toward the structure and therapeutic use of the hairpin ribozyme. Antisense Nucleic Acid Drug Devel., 7, 403-411.
57. Beigelman, L., McSwiggen, J. A., Draper, K. G., Gonzalez, C., Jensen, K., Karpeisky, A. M., Modak, A. S., Matulic-Adamic, J., DiRenzo, A. B., Haeberli, P. (1995). Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J. Biol. Chem., 270, 25702-25708.
58. Usman, N., Blatt, L. M. (2000). Nuclease-resistant synthetic ribozymes: Developing a new class of therapeutics. J. Clin. Invest., 106, 1197-1202.
59. Pieken, W. A., Olsen, D. B., Aurup, H., Williams, D. M., Heidenreich, O., Benseler, F., Eckstein, F. (1991). Structure-function relationship of hammerhead ribozymes as probed by 2¢-modifications. Nucleic Acids Symp. Ser., 51-53.
60. Scherr, M., Rossi, J. J., Sczakiel, G., Patzel, V. (2000). RNA accessibility prediction: A theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res., 28, 2455-2461.
61. Bramlage, B., Luzi, E., Eckstein, F. (2000). HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: Site selection and inhibition in cell culture. Nucleic Acids Res., 28, 4059-4067.
62. Pierce, M. L., Ruffner, D. E. (1998). Construction of a directed hammerhead ribozyme library:Towards the identification of optimal target sites for antisensemediated gene inhibition. Nucleic Acids Res., 26, 5093-5101.
63. Rhoades, K.,Wong-Staal, F. (2003). Inverse genomics as a powerful tool to identify novel targets for the treatment of neurodegenerative diseases. Mech. Ageing Devel., 124, 125-132.
64. Flory, C. M., Pavco, P. A., Jarvis, T. C., Lesch, M. E., Wincott, F. E., Beigelman, L., Hunt, S.W., III, Schrier, D. J. (1996). Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proc. Natl. Acad. Sci. USA, 93, 754-758.
65. Pavco, P. A., Bouhana, K. S., Gallegos, A. M., Agrawal, A., Blanchard, K. S., Grimm, S. L., Jensen, K. L., Andrews, L. E., Wincott, F. E., Pitot, P. A., Tressler, R. J., Cushman, C., Reynolds, M. A., Parry, T. J. (2000). Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer Res., 6, 2094-2103.
66. Sandberg, J. A., Bouhana, K. S., Gallegos, A. M., Agrawal, A. B., Grimm, S. L., Wincott, F. E., Reynolds, M. A., Pavco, P. A., Parry, T. J. (1999). Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse. Antisense Nucleic Acid Drug Devel., 9, 271-277.
67. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., Tuschl, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494-498.
68. Elbashir, S. M., Lendeckel,W., Tuschl, T. (2001). RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Devel., 15, 188-200.
69. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., Mello, C. C. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391, 806-811.
70. Caplen, N. J., Parrish, S., Imani, F., Fire, A., Morgan, R. A. (2001). Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA, 98, 9742-9747.
71. Couzin, J. (2002). Breakthrough of the year. Small RNAs make big splash. Science, 298, 2296-2297.
72. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H., Schreiber, R. D. (1998). How cells respond to interferons. Annu. Rev. Biochem., 67, 227-264.
73. Yuan, B., Latek, R., Hossbach, M., Tuschl, T., Lewitter, F. (2004). siRNA Selection Server: An automated siRNA oligonucleotide prediction server. Nucleic Acids Res., 32, W130-W134.
74. Sioud, M. (2004). Therapeutic siRNAs. Trends Pharmacol. Sci., 25, 22-28.
75. Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li,B., Cavet,G., Linsley, P. S. (2003). Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol., 21, 635-637.
76. Semizarov,D., Frost, L., Sarthy,A., Kroeger, P., Halbert,D. N., Fesik, S.W. (2003). Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl. Acad. Sci. USA, 100, 6347-6352.
77. Sioud, M., Sorensen, D. R. (2003). Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun., 312, 1220-1225.
78. Sioud, M., Sorensen, D. R. (2004). Systemic delivery of synthetic siRNAs. Methods Mol. Biol., 252, 515-522.
79. Amarzguioui, M., Holen, T., Babaie, E., Prydz, H. (2003). Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res., 31, 589-595.
80. Elbashir, S. M., Martinez, J., Patkaniowska, A., Lendeckel,W., Tuschl, T. (2001). Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J., 20, 6877-6888.
81. Braasch, D. A., Jensen, S., Liu,Y., Kaur, K., Arar, K., White, M. A., Corey, D. R. (2003). RNA interference in mammalian cells by chemically-modified RNA. Biochemistry, 42, 7967-7975.
82. Layzer, J. M., McCaffrey, A. P., Tanner, A. K., Huang, Z., Kay, M. A., Sullenger, B. A. (2004). In vivo activity of nuclease-resistant siRNAs. RNA, 10, 766-771.
83. Braasch, D. A., Paroo, Z., Constantinescu, A., Ren, G., Oz, O. K., Mason, R. P., Corey, D. R. (2004). Biodistribution of phosphodiester and phosphorothioate siRN. Bioorg. Med. Chem. Lett., 14, 1139-1143.
84. Zhang, et al. (2003).Vector based RNAi, a novel tool for isoform-specific knockdown of VEGF and anti-angiogenesis gene therapy of cancer. Biochem. Biophys. Res. Commun. 303, 1169-1178.
85. Scherr, et al. (2003). Specific inhibition of Bcr-abl gene expression by small interfering RNA. Blood, 101, 1566-1569.
86. Bullock and Fersht (2001). Rescuing the function of mutant p53. Nat. Rev. Cancer, 1, 68-76.
87. Martinez (2002). Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc. Natl. Acad. Sci. USA, 99, 14849-14854.
88. Zender, L., Hutker, S., Liedtke, C., Tillmann, H. L., Zender, S., Mundt, B., Waltemathe, M., Gosling, T., Flemming, P., Malek, N. P., Trautwein, C., Manns, M. P., Kuhnel, F., Kubicka, S. (2003). Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl. Acad. Sci. USA, 100, 7797-7802.
89. Song, E., Lee, S. K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., Lieberman, J. (2003). RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med., 9, 347-351.
90. Sorensen, D. R., Leirdal, M., Sioud, M. (2003). Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol., 327, 761-766.
91. Lewis, D. L., Hagstrom, J. E., Loomis, A. G., Wolff, J. A., Herweijer, H. (2002). Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet., 32, 107-108.
92. McCaffrey, A. P., Meuse, L., Pham, T. T., Conklin, D. S., Hannon, G. J., Kay, M. A. (2002). RNA interference in adult mice. Nature, 418, 38-39.
93. Templeton, N. S. (2002). Cationic liposome-mediated gene delivery in vivo. Biosci. Rep., 22, 283-295.
94. Liang, L., Liu, D. P., Liang, C. C. (2002). Optimizing the delivery systems of chimeric RNA. DNA oligonucleotides. Eur. J. Biochem., 269, 5753-5758.
95. Jarver, P., Langel, U. (2004). The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov. Today, 9, 395-402.
96. Simeoni, F., Morris, M. C., Heitz, F., Divita, G. (2003). Insight into the mechanism of the peptide-based gene delivery system MPG: Implications for delivery of siRNA into mammalian cells. Nucleic Acids Res., 31, 2717-2724.
97. Kozak, M. (1978). How do eucaryotic ribosomes select initiation regions in messenger RNA? Cell, 15, 1109-1123.
98. Kozak, M. (1999). Initiation of translation in prokaryotes and eukaryotes. Gene, 234, 187-208.
99. Ross, J. (1995). mRNA stability in mammalian cells. Microbiol. Rev., 59, 423-450.
100. Wilusz,C. J.,Wormington, M., Peltz, S.W. (2001).The cap-to-tail guide to mRNA turnover. Nat. Rev. Mol. Cell Biol., 2, 237-246.
101. Chen, C. Y., Shyu, A. B. (1995). AU-rich elements: Characterization and importance in mRNA degradation. Trends Biochem. Sci., 20, 465-470.
102. Holcik, M., Liebhaber, S. A. (1997). Four highly stable eukaryotic mRNAs assemble 3¢ untranslated region RNA-protein complexes sharing cis and trans components. Proc. Natl. Acad. Sci. USA, 94, 2410-2414.
103. Malone, R. W., Felgner, P. L., Verma, I. M. (1989). Cationic liposome-mediated RNA transfection. Proc. Natl. Acad. Sci. USA, 86, 6077-6081.
104. Wolff, J. A., Malone, R.W., Williams, P., Chong,W., Acsadi, G., Jani, A., Felgner, P. L. (1990). Direct gene transfer into mouse muscle in vivo. Science, 247, 1465-1468.
105. Pascolo, S. (2004). Messenger RNA-based vaccines. Exp. Opin. Biol. Ther., 4, 1285-1294.
106. Martinon, F., Krishnan, S., Lenzen, G., Magne, R., Gomard, E., Guillet, J. G., Levy, J. P., Meulien, P. (1993). Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol., 23, 1719-1722.
107. Conry, R. M., LoBuglio, A. F., Wright, M., Sumerel, L., Pike, M. J., Johanning, F., Benjamin, R., Lu,D., Curiel,D. T. (1995). Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res., 55, 1397-400.
108. Hoerr, I., Obst, R., Rammensee, H. G., Jung, G. (2000). In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol., 30, 1-7.
109. Granstein, R. D., Ding,W., Ozawa, H. (2000). Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J. Invest. Dermatol., 114, 632-636.
110. Carralot, J. P., Probst, J., Hoerr, I., Scheel, B., Teufel, R., Jung, G., Rammensee, H., Pascolo, S. (2004). Polarization of the immunity induced by direct injection of naked globin UTR-stabilized mRNA vaccines. Cell Mol. Life Sci.
111. Qiu, P., Ziegelhoffer, P., Sun, J., Yang, N. S. (1996). Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Ther., 3, 262-268.
112. Vassilev, V. B., Gil, L. H., Donis, R. O. (2001). Microparticle-mediated RNA immunization against bovine viral diarrhea virus. Vaccine, 19, 2012-2019.
113. Mandl, C. W., Aberle, J. H., Aberle, S. W., Holzmann, H., Allison, S. L., Heinz, F. X. (1998). In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nat. Med., 4, 1438-1440.
114. Racanelli, V., Behrens, S. E., Aliberti, J., Rehermann, B. (2004). Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8(+) T cells and antiviral immunity. Immunity, 20, 47-58.
115. Schirmacher,V., Forg, P., Dalemans,W., Chlichlia, K., Zeng,Y., Fournier, P., von Hoegen, P. (2000). Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine. Gene Ther., 7, 1137-1147.
116. Ying, H., Zaks, T. Z., Wang, R. F., Irvine, K. R., Kammula, U. S., Marincola, F. M., Leitner,W.W., Restifo, N. P. (1999). Cancer therapy using a self-replicating RNA vaccine. Nat. Med., 5, 823-827.
117. Zhou, X., Berglund, P., Rhodes,G., Parker, S. E., Jondal, M., Liljestrom, P. (1994). Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine, 12, 1510-1514.
118. Boczkowski, D., Nair, S. K., Snyder, D., Gilboa, E. (1996). Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med., 184, 465-472.
119. Sallusto, F., Lanzavecchia,A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colonystimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med., 179, 1109-1118.
120. Heiser, A., Coleman, D., Dannull, J., Yancey, D., Maurice, M. A., Lallas, C. D., Dahm, P., Niedzwiecki, D., Gilboa, E., Vieweg, J. (2002). Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest., 109, 409-417.
121. Morse, M. A., Nair, S. K., Mosca, P. J., Hobeika, A. C., Clay, T. M., Deng, Y., Boczkowski,D., Proia,A., Neidzwiecki,D., Clavien, P. A., Hurwitz, H. I., Schlom, J., Gilboa, E., Lyerly,H. K. (2003). Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest., 21, 341-349.
122. Su, Z., Dannull, J., Heiser, A., Yancey, D., Pruitt, S., Madden, J., Coleman, D., Niedzwiecki, D., Gilboa, E., Vieweg, J. (2003). Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNAtransfected dendritic cells. Cancer Res., 63, 2127-2133.
123. Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., Reis E. S. (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science, 303, 1529-1531.
124. Sieling, P. A., Modlin, R. L. (2002). Toll-like receptors: Mammalian "taste receptors" for a smorgasbord of microbial invaders. Curr. Opin. Microbiol., 5, 70-75.
125. Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., Bauer, S. (2004). Species-specific recognition of singlestranded RNA via toll-like receptor 7 and 8. Science, 303, 1526-1529.
126. Scheel, B., Braedel, S., Probst, J., Carralot, J. P., Wagner, H., Schild, H., Jung, G., Rammensee, H. G., Pascolo, S. (2004). Immunostimulating capacities of stabilized RNA molecules. Eur. J. Immunol., 34, 537-547.
127. Pimm, M. V., Embleton, M. J., Baldwin, R.W. (1976). Treatment of transplanted rat tumours with double-stranded RNA (BRL 5907). I. Influence of systemic and local administration. Br. J. Cancer, 33, 154-165.
128. Carter, W. A., Strayer, D. R., Hubbell, H. R., Brodsky, I. (1985). Preclinical studies with Ampligen (mismatched double-stranded RNA). J. Biol. Response Mod., 4, 495-502.
129. Brodsky, I., Strayer, D. R., Krueger, L. J., Carter,W. A. (1985). Clinical studies with ampligen (mismatched double-stranded RNA). J. Biol. Response Mod., 4, 669-675.
130. Schroder, H. C., Kelve, M., Schacke, H., Pfleiderer, W., Charubala, R., Suhadolnik, R. J., Muller, W. E. (1994). Inhibition of DNA topoisomerase I activity by 2¢, 5¢-oligoadenylates and mismatched double-stranded RNA in uninfected and HIV-1-infected H9 cells. Chem. Biol. Interact., 90, 169-183.
131. Thompson, K. A., Strayer, D. R., Salvato, P. D., Thompson, C. E., Klimas, N., Molavi, A., Hamill, A. K., Zheng, Z., Ventura, D., Carter,W. A. (1996). Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Eur. J. Clin. Microbiol. Infect. Dis., 15, 580-587.
132. Essey, R. J., McDougall, B. R., Robinson,W. E., Jr. (2001). Mismatched doublestranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. Antiviral Res., 51, 189-202.
133. Adams, M., Navabi, H., Jasani, B., Man, S., Fiander, A., Evans, A. S., Donninger, C., Mason, M. (2003). Dendritic cell (DC) based therapy for cervical cancer: Use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine, 21, 787-790.
134. Scaringe, S. A., Francklyn, C., Usman, N. (1990). Chemical synthesis of biologically active oligoribonucleotides using beta-cyanoethyl protected ribonucleoside phosphoramidites. Nucleic Acids Res., 18, 5433-5441.
135. Scaringe, S. A., Wincott, F. E., Caruthers, M. H. (1998). Novel RNA synthesis method using 5¢-silyl-2¢-orthoester protecting groups. J. Am. Chem. Soc., 120, 11820-11821.
136. Kambhampati, R. V., Chiu, Y. Y., Chen, C. W., Blumenstein, J. J. (1993). Regulatory concerns for the chemistry, manufacturing, and controls of oligonucleotide therapeutics for use in clinical studies. Antisense Res. Devel., 3, 405-410.
137. Azarani,A., Hecker,K. H. (2001). RNA analysis by ion-pair reversed-phase high performance liquid chromatography. Nucleic Acids Res., 29, E7.